A common mechanism by which the tumor suppressor p53 accumulates in the nucleus following cellular stress is through the attenuation of its interaction with MDM2, a protein involved in the nuclear export and degradation of p53. This is accomplished by induced modifications of p53, MDM2 or both. We have previously found that the kinase and mRNA synthesis inhibitor DRB (5,6-dichloro-1-b-D-ribofuranosylbenzimidazole) induces the nuclear accumulation of p53 without concomitant phosphorylation of the ser15 site of p53, which is thought to be a modification important for the attenuation of p53-MDM2 interaction. It has been proposed that the mechanism by which p53 accumulates following blockage of transcription involves the downregulation of MDM2 expression. In this study, we tested this hypothesis and found that after DRB treatment, p53 accumulated despite the fact that MDM2 levels remained high in human cells. Furthermore, over expression of MDM2 did not prevent the accumulation of p53 following DRB treatment. In, addition, p53 accumulating in the nucleus after DRB treatment was able to interact with MDM2 and was ubiquitylated. These findings suggest that blockage of transcription induce the nuclear accumulation of p53 without breaking the p53-MDM2 regulation loop.
Introduction
The tumor suppressor p53 is a transcription factor that plays an important role in a cell's response to DNA damage either by causing damaged cells to undergo apoptosis (Symonds et al., 1994) or by inducing cell cycle arrest to give the cell time to repair the damage (Dulic et al., 1994) . In unstressed cells, p53 is maintained at low levels but after DNA damage p53 accumulates in the nuclei of cells (Rotter et al., 1983; Kastan et al., 1991; Lowe and Ruley, 1993) . The level and nuclear localization of p53 are under tight control to keep p53 inactive when it is not needed but to quickly induce a p53 response when necessary.
To maintain p53 at a low level, p53 is exported out of the nucleus and degraded in a proteasome-dependent manner (Maki et al., 1996) . MDM2 is a protein that is transcriptionally induced by p53 and is also involved in the export and degradation of p53, making MDM2 part of a negative feedback loop regulating p53 levels in cells (Wu et al., 1993; Haupt et al., 1997; Kubbutat et al., 1997) . MDM2 acts as an ubiquitin ligase for p53 by binding to the amino-terminal end of p53 and transferring ubiquitin groups to p53 (Honda et al., 1997; Nakamura et al., 2000; Rodriguez et al., 2000) . The mechanism by which MDM2 directs p53 export and degradation requires both the binding of MDM2 to p53 and the addition of ubiquitin groups to p53 (Boyd et al., 2000; Geyer et al., 2000) . Most p53 is thought to be degraded in the cytoplasm by the 26S proteasome, but some reports suggest that nuclear degradation of p53 may also occur (Xirodimas et al., 2001; Joseph et al., 2003) .
The accumulation of p53 proteins has been shown to occur in the nuclei of cells in response to agents that damage DNA and/or inhibit transcription (Maltzman and Czyzyk, 1984; Ljungman and Zhang, 1996; Maki and Howley, 1997; Ljungman et al., 1999) . The exact mechanism of accumulation is not known but the halflife of p53 is increased, suggesting that part of the mechanism involves protecting p53 from degradation (Ashcroft et al., 1999) . Several of the agents that activate p53, such as ionizing radiation and ultraviolet (UV) light, activate kinases that phosphorylate p53 at specific N-terminal residues (Siliciano et al., 1997; Banin et al., 1998; Canman et al., 1998; Khanna et al., 1998) . It is thought that such phosphorylations block the binding of MDM2 to p53 resulting in the nuclear accumulation and stabilization of p53 (Shieh et al., 1997 (Shieh et al., , 1999 Siliciano et al., 1997; Craig et al., 1999; Unger et al., 1999; Kapoor et al., 2000; Zhang and Xiong, 2001 ). However, it has been shown that mutant p53 that cannot be phosphorylated at these amino-terminal residues can still be stabilized by low doses of UV radiation or by treatment with actinomycin D, suggesting that other mechanisms for p53 stabilization exist (Ashcroft et al., 1999; Blattner et al., 1999b) .
One possible mechanism for the stabilization of p53 without concomitant protein modifications is through the inhibition of MDM2 expression. It has been shown that the protein and mRNA levels of MDM2 decrease initially after treatment with camptothecin (Ashcroft et al., 2000) , UV light (Wu and Levine, 1997) , nitric oxide (Wang et al., 2002) and the topoisomerase II inhibitor, etoposide (Arriola et al., 1999) . This decrease in MDM2 levels might initially cause p53 to be stabilized and accumulate in the nucleus. Also, the DNA alkylating agents mitomycin C and methylmethane sulfonate have been found to cause a decrease in MDM2 mRNA and proteins levels in RKO cells that coincide with an increase in p53 levels and a decrease in the amounts of ubiquitylated p53 and p53:MDM2 complexes (Inoue et al., 2001) . The induction of p53 by these agents could be blocked by a transient overexpression of MDM2, suggesting that the decrease in MDM2 levels may in part have been responsible for the stabilization of p53. These results contrast other findings that show that p53 can accumulate following transcription interference even though MDM2 levels remain high (Ashcroft et al., 2000; Wang et al., 2003) . After treatment with a low level of actinomycin D that primarily inhibits RNA polymerase I, p53 is stable and transcriptionally active even though high levels of MDM2 are present (Ashcroft et al., 2000) . The accumulated p53 was shown to be unphosphorylated and could interact with MDM2 in vitro, while in cells MDM2 and p53 proteins most likely do not interact because they are expected to be sequestered to different areas of the nucleus (Ashcroft et al., 2000) . At higher doses of actinomycin D that significantly inhibit RNA polymerase II transcription, p53 does become phosphorylated at ser15 and therefore might accumulate by avoiding interaction with MDM2 . Furthermore, treatment of cells with CP-31398, a therapeutic agent that maintains p53 in an active conformation, stabilizes p53 even though MDM2 levels increase and the interaction between MDM2 and p53 is maintained (Wang et al., 2003) . The mechanism of p53 stabilization by this drug is suggested to involve the inhibition of ubiquitylation of p53.
DRB (5, 6-dichloro-1-b-D-ribofuranosylbenzimidazole) is a kinase inhibitor that can inhibit transcription by blocking the phosphorylation of the carboxyterminal domain of RNA polymerase II leading to the blockage of the transition from transcription initiation to elongation (Dubois et al., 1994) . Treatment of human fibroblasts with DRB results in p53 accumulation without concomitant phosphorylation of the ser15 site of p53 O'Hagan and Ljungman, 2004) . As DRB can inhibit transcription and accumulate p53 without inducing phosphorylation of the ser15 site, one possibility is that DRB induces nuclear accumulation of p53 by reducing the level of MDM2 protein.
In this study, we tested the hypothesis that p53 accumulation induced by DRB is due to diminished MDM2 protein levels. First, we assessed p53 accumulation after DRB treatment in the colon cancer cell line SJSA that has high endogenous MDM2 levels. Second, we investigated whether overexpression of MDM2 in normal fibroblasts prevents the nuclear accumulation of p53 following DRB treatment. Third, we explored whether MDM2 and p53 interact following DRB treatment and fourth, whether the accumulated p53 is ubiquitylated.
Results

DRB induces nuclear accumulation of p53 in cells with high levels of endogenous MDM2
To test whether the endogenous level of MDM2 after DRB treatment may influence the accumulation of p53, we used the SJSA colon cancer cell line that overexpresses MDM2 due to a gene amplification of the MDM2 gene (Leach et al., 1993; Chen et al., 1999) . Consequently, these cells express very low levels of p53. In order to assess if MDM2 levels change with DRB treatment and if DRB could induce the nuclear accumulation of p53 in MDM2-overexpressing cells, we treated both human fibroblasts and SJSA cells with 20 mM DRB. We found that MDM2 protein levels were high in SJSA cells both before and after treatment, suggesting that DRB treatment did not reduce MDM2 levels significantly in these cells at any time point (Figure 1a) . Levels of MDM2 protein also remained basically constant in normal fibroblasts during the treatment periods. We next investigated whether the p53 levels changed in these cells following DRB treatment. It was found that even though the MDM2 protein level remained high in SJSA cells following DRB treatment, p53 protein levels increased (Figure 1a ). The accumulated p53 was localized to the nuclei of SJSA cells as shown by immunocytochemistry (Figure 1c ). We conclude that even in the presence of high levels of endogenous MDM2, DRB induces the nuclear accumulation of p53.
In agreement with previous results O'Hagan and Ljungman, 2004) , the level of phosphorylation of the ser15 site of p53 remained low after DRB treatment compared to the level induced following UV irradiation ( Figure 1a ). These results suggest that after DRB treatment, p53 accumulation precedes the phosphorylation of the ser15 site of p53 and that most of the accumulated p53 is unphosphorylated at this residue. Even though phosphorylation of p53 on ser15 enhances transcriptional activation of p53 (Dumaz and Meek, 1999; Bean and Stark, 2001) , it is possible that an increased level of nuclear p53 is sufficient for enhanced transactivation. In this study, we found that induction of p53 by DRB treatment correlated with increased expression of the p21 protein in human fibroblasts, suggesting that the accumulated p53 was able to transactivate the p21 gene ( Figure 1a ). However, no induction of the expression of the MDM2 protein was noted in these cells, nor did we observe induction above the high constitutive levels of either p21 or MDM2 in DRB-treated SJSA cells (Figure 1b) .
Overexpression of MDM2 protein from an exogenous vector does not prevent the induction of the nuclear accumulation of p53 after DRB treatment
We next determined whether increasing the levels of MDM2 in cells normally expressing low levels of MDM2 would affect the ability of DRB to accumulate p53. To accomplish this, we overexpressed MDM2 protein by microinjection of a plasmid encoding CMV-MDM2 into the nuclei of HT29C cells that have high basal levels of mutant p53 localized to the nucleus. Since the mutant form of p53 in these cells has a defective DNA-binding domain, it is not able to transactivate its target genes. Consequently, the cells have very low levels of MDM2 resulting in the accumulation of p53. Immunocytochemistry was used to determine the localization of p53 and MDM2 in cells microinjected with the MDM2 expression vector (Figure 2 ). Cells that had been microinjected with the CMV-MDM2 vector expressed high levels of MDM2 at 6 h and had significantly decreased levels of nuclear p53 compared to their noninjected neighbors, suggesting that the MDM2 proteins expressed from the exogenous vector were functional.
To explore whether the MDM2 proteins expressed from the exogenous vectors were able to prevent the nuclear accumulation of p53 after DRB treatment, we microinjected human fibroblasts with the CMV-MDM2 plasmid, incubated for 4 h to allow for expression, and then treated for 2 h with DRB. After treatment, cells were fixed and p53 and MDM2 were visualized by immunocytochemistry (Figure 2 ). Cells microinjected with the CMV-MDM2 plasmids expressed high levels of MDM2, but this enhanced level of expression did not appear to affect the level or localization of p53, which was very low and mostly localized to the cytoplasm in both control and microinjected cells. The MDM2 Figure 2 Overexpression of exogenous MDM2 does not diminish p53 accumulation following DRB treatment. HT29 cells expressing high levels of mutant nuclear p53 were microinjected with CMV-MDM2 expression plasmid, incubated for 6 h at 371C and then fixed with methanol:acetone (left panels). Localization of p53 and MDM2 was assessed by immunocytochemistry and DNA was visualized using Hoechst stain. The results show that the expression of exogenous MDM2 resulted in the complete loss of nuclear p53. Normal fibroblasts were microinjected with CMV-MDM2 expression plasmid and incubated either continuously for 6 h in drug-free media or were incubated for 4 h in untreated media followed by 2 h in the media containing 20 mM DRB. Cells were then fixed and localization of p53 and MDM2 was determined by immunocytochemistry and DNA was visualized using Hoechst stain 2 UVC light and collected 6 h later were used as positive controls. Cell lysates were run on a 10% SDS-PAGE gel. Commassie blue staining of the membranes was performed to ensure that each lane was loaded with similar amounts of total protein. (c) Cells were mock treated or treated with 20 mM DRB for 6 h and fixed. Localization of p53 was detected by immunocytochemistry using anti-p53 antibodies and DNA was visualized using Hoechst stain Induction of p53 by transcription blockage HM O'Hagan and M Ljungman expressed in cells microinjected with the CMV-MDM2 plasmid was mostly localized to the nucleus in accord with previous studies (Haupt et al., 1997; Boyd et al., 2000; Geyer et al., 2000) . Moreover, DRB treatment of cells expressing CMV-MDM2 from the exogenous vector accumulated p53 to similar levels as noninjected neighbors. We found that 90% of cells expressing the CMV-MDM2 vector expressed high levels of nuclear p53 compared to 97% of noninjected neighbor cells (data not shown). These results suggest that p53 accumulated in the nuclei of cells after DRB treatment despite the presence of high levels of MDM2 protein.
DRB treatment does not interrupt the physical interaction between p53 and MDM2
In an attempt to determine the mechanism of p53 nuclear accumulation after DRB treatment, we next explored whether DRB interferes with the interaction between p53 and MDM2. Both human fibroblasts and SJSA cells were treated for 6 h with 20 mM DRB, 10 J/m 2 UV or 5 mM MG132 followed by immunoprecipitation with anti-MDM2 antibodies and Western blot with antip53 antibodies. As expected, only small amounts of p53 co-immunoprecipitated with MDM2 under control conditions because p53 levels are low in unstressed cells (Figure 3a and b) . Even though p53 accumulated after UV treatment, very little p53 protein immunoprecipitated with MDM2 probably because UV light induced phosphorylation of the ser15 site of p53 disrupts its interaction with MDM2. After UV treatment, the levels of MDM2 appeared to decrease compared to control levels in both the input and anti-MDM2 immunoprecipitated lanes. This could be due to phosphorylation of MDM2, which has been shown to reduce the ability of the 2A10 anti-MDM2 antibody (Ab) (used in these studies) to recognize MDM2 (Khosravi et al., 1999; Maya et al., 2001; Shinozaki et al., 2003) . Importantly, we did not see a similar decrease of MDM2 levels following DRB treatment, suggesting that DRB may not induce MDM2 phosphorylation.
It has been shown that the proteasome inhibitor MG132 induces the nuclear accumulation of p53 by sequestering the proteins to the nucleolus without attenuating the interaction between p53 and MDM2 (Lopes et al., 1997; Klibanov et al., 2001; Latonen et al., 2003; Schneiderhan et al., 2003) . Here, we show that treatment with MG132 accumulated p53 and that these p53 proteins were capable of interacting with MDM2. Furthermore, DRB treatment resulted in p53 accumulation and antibodies to MDM2 were able to immunoprecipitate p53 proteins both in normal fibroblasts and in SJSA cells treated with DRB (Figure 3a and b, respectively). Reciprocal immunoprecipitations were preformed in SJSA cells with anti-p53 antibodies and similar results were found (Figure 3c ). We conclude that accumulation of p53 following DRB treatment is not due to diminished interaction between p53 and MDM2.
p53 is ubiquitylated following DRB treatment
Since MDM2 and p53 were found to interact with each other following DRB treatment, it is possible that DRB causes the nuclear accumulation of p53 by preventing the MDM2-mediated ubiquitylation of p53. In fact, it 2 UV or 5 mM MG132 for 6 h. Cell lysates were incubated overnight at 41C with anti-MDM2 antibodies or with no Ab (ÀAb). Bound protein was eluted by boiling and samples were run on a 10% SDS-PAGE gel and the amounts of p53 that co-IP with MDM2 were assessed by immunoblotting using an anti-p53 Ab. The input levels of p53 and MDM2 were assessed by running whole-cell lysates on a 10% SDS-PAGE gel and by immunoblotting using anti-MDM2 and anti-p53 antibodies. (c) SJSA cells were treated as in (a) except cell lysates were immunoprecipitated with anti-p53 antibodies and the amounts of MDM2 that co-IP with p53 were assessed by immunoblotting using an anti-MDM2 Ab Induction of p53 by transcription blockage HM O'Hagan and M Ljungman has been shown that mutant MDM2 that cannot ubiquitylate p53 is defective in its ability to facilitate p53's nuclear export (Haupt et al., 1997) . In order to assess whether p53 is ubiquitylated after DRB treatment, we treated normal fibroblasts and SJSA cells with DRB and compared the level of p53 ubiquitylation with the level induced following UV or MG132 treatment. After a 6-h incubation with DRB, the cells were lysed and p53 was immunoprecipitated. Ubiquitylated forms of p53 were visualized on an SDS-PAGE gel as a ladder of slower migrating bands from 60 to 130 kda (Maki et al., 1996; Maki and Howley, 1997) . We found that after UV light, there was very little ubiquitylated p53 as expected because both p53 and MDM2 are phosphorylated following UV irradiation, which is thought to diminish the interaction between them (Figure 4) . Conversely, p53 isolated from cells treated with MG132 was highly ubiquitylated because the accumulated p53 is not phosphorylated at ser15 and can bind to and be ubiquitylated by MDM2. Importantly, we found that the level of ubiquitylated p53 after DRB treatment was similar to that found after MG132 treatment, suggesting that DRB does not interfere with the ubiquitylation of p53. We suggest that this level of ubiquitylation of p53 after DRB treatment is significant because even though similar amounts of p53 were immunoprecipitated from SJSA cells treated with UV light, no evidence of ubiquitylation of p53 was detected in those samples. The more distinct ladder observed for ubiquitylated p53 in SJSA cells after treatment is most likely due to the higher levels of MDM2 present in these cells resulting in a more complete ubiquitylation of p53. Taken together, our results suggest that the p53 proteins accumulating in the nucleus during DRB treatment can bind MDM2 and a significant portion of this population is highly ubiquitylated.
Discussion
The mechanism by which p53 accumulates and is activated after cellular stresses is not fully understood.
Many p53-inducing agents trigger signal transduction pathways that result in modifications of p53. Phosphorylation and acetylation are thought to play important roles in the increase of p53 stability by interfering with the binding of MDM2 to p53, thereby abrogating nuclear export and degradation of p53 (for a review see Ljungman, 2000) . Phosphorylation of the ser15 site of p53 is thought to result in a cascade of additional modifications that reduce MDM2 binding and accumulate p53 in the nucleus. We have previously shown that DRB, an agent that inhibits transcription, induces the nuclear accumulation of p53 without concurrent phosphorylation of the ser15 site O'Hagan and Ljungman, 2004) . Here, we present results showing that DRB induces the nuclear accumulation of p53 neither by diminished MDM2 protein levels nor by interference with the binding of p53 to MDM2. Furthermore, we show that a large portion of the accumulated p53 proteins is highly ubiquitylated in DRB-treated cells. These results suggest that DRB induces the accumulation of p53 without breaking the p53-MDM2 feedback loop. Previously, it was proposed that the mechanism of accumulation of p53 after DRB treatment was due to an initial decrease in MDM2 levels (Blattner et al., 1999a) similar to what has been demonstrated for other agents (Wu and Levine, 1997; Arriola et al., 1999; Ashcroft et al., 2000; Wang et al., 2002) . In contrast to these findings, we found no initial decrease in MDM2 protein levels at short time points, suggesting that a downregulation of MDM2 protein levels may not be responsible for the accumulation of p53 in DRB-treated cells. An explanation for the discrepancy between our work and the previous findings could be that the dose of DRB used in the previous study was 250 mM compared to the 20 mM concentration used in our experiments. A concentration of 20 mM DRB reduces mRNA synthesis by about 45% in human cells (Ljungman et al., 1999) , which may allow for some continued expression of the MDM2 gene.
It is known that p53 is a nucleocytoplasmic shuttling protein that contains nuclear localization sequences and leucine-rich nuclear export sequences (NESs), which are recognized by the nuclear transport factor CRM-1 (Shaulsky et al., 1990; Stommel et al., 1999; Zhang and Xiong, 2001) . A reduction in the nuclear export or an increase in the nuclear import could conceivably shift the steady-state localization of p53 in cells from the cytoplasm to the nucleus. Blockage of nuclear export of p53 by treatment with leptomycin B, a specific inhibitor of CRM1, causes the accumulation of nuclear p53 that is ubiquitylated . This result suggests that attenuation of nuclear export could cause the nuclear localization and accumulation of p53 even if it is ubiquitylated. Therefore, blockage of p53 nuclear export could be an explanation for how p53 accumulates after DRB treatment.
The nuclear export of p53 under nonstressed conditions has been suggested to depend on a functional nucleolar structure (Tao and Levine, 1999; Sherr and Weber, 2000) . In fact, we have previously shown that (Klibanov et al., 2001) . However, this association with nucleoli appeared to occur subsequent to the nuclear accumulation of p53, suggesting that blockage of nucleolar-mediated nuclear export was not exclusively responsible for the p53 induction under these circumstances. A recent report suggests that stress-induced impairment of the nucleolus might be the mechanism by which DRB and other agents stabilize p53 (Rubbi and Milner, 2003) . It was shown that agents such as DRB disrupt the structure of the nucleoli and further demonstrated that nucleolar disruption without concomitant DNA damage or metabolic stress was sufficient for the accumulation of p53. This model suggests that the accumulation of p53 in the nuclei of DRB-treated cells may be linked to the loss of nucleolar structure leading to the attenuation of nuclear export of p53 despite of its interaction with MDM2 and its ubiquitylated state. From our work, it is not possible to distinguish between the contributing roles of blocked transcription and the disruption of the nucleolar structure for p53 accumulation following DRB treatment, since it is thought that the nucleolar alterations are the result of DRB's RNA polymerase II inhibiting activity (Scheer et al., 1984; Scheer and Benavente, 1990; David-Pfeuty et al., 2001) . Determining the relative timing of inhibition of RNA synthesis, nucleolar disruption and p53 accumulation is needed to elucidate which may be the causative factor.
Since p53 is an RNA-binding protein, it is possible that the nuclear export of p53 is dependent on the synthesis and nuclear export of RNA. Thus, agents that interfere with transcription may cause p53 to accumulate in the nucleus due to the decrease of RNA molecules to be exported. In support of this hypothesis, we have recently found that inhibition of transcription along with blockage of RNA nuclear export causes a reduction of generic NES-mediated protein nuclear export (O'Hagan and Ljungman, submitted) . We hypothesize that the blockage of NES-mediated nuclear export following inhibition of transcription is due to a reduction in the level of mRNA available for nuclear export. It is possible that the accumulation of p53 observed after treatment with DRB and other agents that inhibit transcription is due to diminished levels of mRNAs involved in facilitating NES-mediated export.
Clearly, there are multiple mechanisms by which p53 accumulates in cells following stress. In this study, we show that inhibition of transcription by DRB results in the accumulation of nuclear p53 despite sustained cellular levels of MDM2. Furthermore, MDM2 was found to interact with p53 and a substantial population of p53 was found to be ubiquitylated following DRB treatment. Thus, the mechanism by which DRB causes accumulation of p53 does not seem to involve the breakage of the p53-MDM2 regulatory loop. Further studies are required to elucidate the true mechanism by which inhibition of transcription causes the nuclear accumulation of p53.
Materials and methods
Cell culture, irradiation and chemicals
Diploid human fibroblasts were grown as monolayers on culture dishes or on covers slips in MEM supplemented with 10% fetal bovine serum (FBS) and antibiotic/antimycotic (GIBCO BRL). SJSA colon cancer cells were grown on culture dishes in RPMI supplemented with 10% FBS and penicillin/ streptomycin (GIBCO BRL). Cells were irradiated at room temperature with a germicidal UV light (254 nm). The fluence of the UV light source (Philips) was measured prior to each experiment with a UVX radiometer (UVP, Inc.). DRB and MG132 were purchased from Sigma. Stock solutions were prepared at the concentration of 50 mM in ethanol for DRB or 10 mM in DMSO for MG132.
Immunocytochemistry
Human fibroblasts or SJSA cells grown on coverslips were treated with DRB (20 mM) for 6 h, washed with phosphatebuffered saline (PBS), fixed in ice-cold methanol/acetone (1 : 1) and stored at À201C for 15 min. The fixed cells were rinsed twice in PBS and incubated for 1 h at 371C with the mouse monoclonal anti-p53 Ab 1801 (a gift from Dr Jiayuh Lin, University of Michigan). The Ab solution was aspirated and the cells were rinsed three times with PBSBT (5 g bovine albumin and 500 ml Tween-20 per liter of PBS). The cells were then incubated for 1 h at 371C in the dark with a secondary FITC-conjugated anti-mouse IgG Ab (Sigma, 1 : 1000 dilution in PBSBT). Following two rinses in PBSBT, the coverslips were mounted on microscope slides in one drop of Vectashield (Vector Laboratories, Inc.). Images were captured digitally using a Nikon Eclipse E600 fluorescent microscope with a Plan-Fluor 100 Â /1.30 oil lens and a Cool Snap-Pro/ef digital camera (Media Cybernetics).
Western blot analysis
Human fibroblasts or SJSA cells were treated with 20 mM DRB for 6 h or as stated in figure legends. Cells were then rinsed with PBS, detached by scraping and collected by centrifugation. Protein concentration was quantified using a protein assay (BioRad) and approximately 10 mg of protein were loaded per lane. The samples were boiled for 5 min in SDS loading buffer (2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.05% bromophenol blue and 62.5 mM Tris pH 6.8) prior to loading. Following SDS-PAGE, proteins were electrophoretically transferred to Immobilon-P transfer membranes (Millipore) using the Trans-Blot Semi-Dry Electrophoretic transfer cell (Bio Rad). Antibodies used for the Western blot were the mouse anti-p53 Ab (Ab-2, Oncogene Research Products), the mouse monoclonal anti-MDM2 (ZA-10, a gift from Dr. J. Lin, University of Michigan), the rabbit antiPhospho-p53 (ser15) Ab (Cellular Signaling Technology) and the mouse anti-WAF1/p21 Ab (Ab-1, Oncogene Research Products). X-ray film (Biomax AR, Amersham) and enhanced chemiluminescence (Super Signal CL-HRP Substrate System, Pierce) were used to visualize p53 and MDM2 proteins.
Cellular microinjections
CMV-MDM2 expression plasmid was microinjected into the nuclei of HT29 cells or human fibroblasts at a concentration of 2 mg/ml. Microinjection was performed using a computerassisted AIS 2 R MicroManipulation System from Cell Biology Trading Company attached to a Zeiss Axiovert 200 microscope. After microinjection, cells were incubated at 371C for 6 h or incubated for 4 h and then treated with 20 mM DRB for 4 h. Cells were then fixed using 3.7% paraformaldehyde followed by permeabilization with permeabilization buffer (PBS þ 0.2% Triton-X þ 0.5% bovine serum albumin (BSA)). Proteins were localized as described for immunocytochemistry except that the primary antibodies used were the mouse monoclonal anti-MDM2 (ZA-10) and the rabbit monoclonal anti-p53 Ab (FL, Santa Cruz Biotechonology). The secondary antibodies used were FITC-conjugated anti-rabbit IgG Ab (Sigma, 1 : 1000 dilution in Permeabilization buffer) and TRITC conjugated anti-mouse IgG Ab (Sigma, 1 : 1000 dilution in PBSBT).
Immunoprecipitations
Human fibroblasts or SJSA cells were treated with 20 mM DRB, 10 J/m 2 UV or 5 mM MG132 for 6 h. Cells were collected by scraping into cold PBS plus proteasome inhibitors (Complete MINI PI cocktail inhibitor tablets, Roche). Cells were lysed in NP-40 buffer (150 mM NaCl, 1% NP-40, 50 mM Tris pH 8.0) for 15 min at 41C. Protein concentration was quantified using a protein assay (BioRad) and approximately 0.2 mg of protein was used per co-immunoprecipitation (CO-IP). Cell lysates were incubated overnight at 41C with either anti-MDM2 Ab (Ab-1, Oncogene) or anti-p53 Ab (FL, Santa Cruz Biotechnologies). Samples were then incubated with prewashed protein A/G PLUS-agarose (Santa Cruz Biotechnologies) for 4 h at 41C. Beads were then collected and washed two times with NP-40 buffer. Proteins were eluted by boiling the beads in SDS loading buffer for 8 min. The supernatant was then run on an 8% or 10% SDS-PAGE and proteins were visualized as described for Western blots using anti-MDM2 antibodies (Ab-1), mouse monoclonal anti-MDM2 (2A10), anti-p53 antibodies (FL) or anti-p53 antibodies (Ab-6, Oncogene). Owing to different optimal SDS-PAGE running conditions for the antibodies used, it was not feasible to perform both anti-MDM2 and anti-p53 immunoblotting from the same immunoprecipitate. Therefore, blots from two identical experiments are presented in Figure 3 .
